EAM Investors LLC Sells 33,257 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON)

EAM Investors LLC lowered its position in shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Free Report) by 25.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 95,019 shares of the company's stock after selling 33,257 shares during the period. EAM Investors LLC owned 0.36% of Eton Pharmaceuticals worth $1,266,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Westside Investment Management Inc. increased its holdings in shares of Eton Pharmaceuticals by 5.7% in the third quarter. Westside Investment Management Inc. now owns 618,675 shares of the company's stock worth $3,711,000 after purchasing an additional 33,275 shares during the period. Cannell Capital LLC bought a new position in Eton Pharmaceuticals in the 4th quarter worth about $5,079,000. Geode Capital Management LLC raised its holdings in shares of Eton Pharmaceuticals by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 272,696 shares of the company's stock valued at $1,637,000 after acquiring an additional 32,365 shares in the last quarter. Aristides Capital LLC boosted its position in shares of Eton Pharmaceuticals by 20.8% during the 4th quarter. Aristides Capital LLC now owns 241,587 shares of the company's stock valued at $3,218,000 after acquiring an additional 41,587 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Eton Pharmaceuticals by 230.5% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 214,878 shares of the company's stock worth $2,862,000 after purchasing an additional 149,864 shares in the last quarter. Institutional investors own 27.86% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ETON shares. B. Riley reiterated a "buy" rating and set a $24.00 target price (up from $21.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, March 19th. Craig Hallum increased their target price on Eton Pharmaceuticals from $23.00 to $26.00 and gave the company a "buy" rating in a research note on Wednesday, March 19th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $33.00 price target on shares of Eton Pharmaceuticals in a research note on Wednesday, March 19th.

Eton Pharmaceuticals Price Performance

NASDAQ ETON traded up $0.59 during trading on Tuesday, hitting $14.85. 47,009 shares of the company's stock traded hands, compared to its average volume of 173,446. The firm has a market cap of $398.33 million, a P/E ratio of -67.67 and a beta of 1.34. The stock has a fifty day moving average of $14.14 and a two-hundred day moving average of $12.80. Eton Pharmaceuticals, Inc. has a 12-month low of $3.11 and a 12-month high of $18.41.

Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last announced its quarterly earnings results on Tuesday, March 18th. The company reported ($0.02) EPS for the quarter, hitting analysts' consensus estimates of ($0.02). The business had revenue of $11.65 million for the quarter, compared to analysts' expectations of $10.53 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. As a group, analysts expect that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current fiscal year.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.